Alyssum Therapeutics Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $28M

  • Investors
  • 10

Alyssum Therapeutics General Information

Description

Developer of supramolecular therapeutics designed for cancer patients. The company offers treatments and antibody drugs to treat lung, testicular, colorectal, and childhood cancers, its therapeutics use supra-molecular technology to design anti-cancer drugs that home in on the tumor and modulate the tumor immune response, enabling oncologists to outsmart cancer cells in patients by activating the immune system.

Contact Information

Formerly Known As
Akamara Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 626 Massachusetts Avenue
  • 2nd floor
  • Cambridge, MA 02139
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • 626 Massachusetts Avenue
  • 2nd floor
  • Cambridge, MA 02139
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alyssum Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 08-Jan-2025 $28M Completed Clinical Trials - Phase 1
5. Later Stage VC 29-Oct-2021 Completed Clinical Trials - Phase 1
4. Secondary Transaction - Private 01-Mar-2021 Completed Clinical Trials - Phase 1
3. Later Stage VC (Series B) 28-Mar-2017 Completed Clinical Trials - Phase 1
2. Later Stage VC 08-Feb-2016 $1.92M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 28-May-2013 $1.92M $1.92M Completed Product Development
To view Alyssum Therapeutics’s complete valuation and funding history, request access »

Alyssum Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preference
CCPS
Preference
CCPS 5,000 $0.151382 $151.38 $151.38 1x $151.38 6.99%
Preference 5,000 $0.151382 $151.38 $151.38 1x $151.38 6.99%
To view Alyssum Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alyssum Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of supramolecular therapeutics designed for cancer patients. The company offers treatments and antibody drugs
Drug Discovery
Cambridge, MA
4 As of 2025

Boston, MA
 

Plymouth Meeting, PA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alyssum Therapeutics Competitors (27)

One of Alyssum Therapeutics’s 27 competitors is IFM Therapeutics, a Venture Capital-Backed company based in Boston, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
IFM Therapeutics Venture Capital-Backed Boston, MA
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Gamida Cell Formerly VC-backed Boston, MA
Kite Pharma Formerly VC-backed Santa Monica, CA
Auron Therapeutics Venture Capital-Backed Newton, MA
You’re viewing 5 of 27 competitors. Get the full list »

Alyssum Therapeutics Patents

Alyssum Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12357699-B2 B-cell immunotherapy in cancer treatment Active 10-Jul-2018
WO-2018146641-A1 Novel inhibitors of cellular signalling Inactive 11-Feb-2017
WO-2018009527-A1 Evaluation and optimization of supramolecular therapeutics Inactive 05-Jul-2016
WO-2017199201-A1 Crystalline platinum-based compounds Inactive 18-May-2016
AU-2017218772-A1 Cellular signalling inhibitors, their formulations and methods thereof Inactive 11-Feb-2016 A61K47/554
To view Alyssum Therapeutics’s complete patent history, request access »

Alyssum Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alyssum Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Famy (India) Corporation Minority
Angel (individual) Minority
FemHealth Ventures Venture Capital Minority
Accel Venture Capital Minority
REMUS Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Alyssum Therapeutics FAQs

  • When was Alyssum Therapeutics founded?

    Alyssum Therapeutics was founded in 2011.

  • Where is Alyssum Therapeutics headquartered?

    Alyssum Therapeutics is headquartered in Cambridge, MA.

  • What is the size of Alyssum Therapeutics?

    Alyssum Therapeutics has 4 total employees.

  • What industry is Alyssum Therapeutics in?

    Alyssum Therapeutics’s primary industry is Drug Discovery.

  • Is Alyssum Therapeutics a private or public company?

    Alyssum Therapeutics is a Private company.

  • What is Alyssum Therapeutics’s current revenue?

    The current revenue for Alyssum Therapeutics is .

  • How much funding has Alyssum Therapeutics raised over time?

    Alyssum Therapeutics has raised $32.7M.

  • Who are Alyssum Therapeutics’s investors?

    Famy (India), , FemHealth Ventures, Accel, and REMUS Capital are 5 of 10 investors who have invested in Alyssum Therapeutics.

  • Who are Alyssum Therapeutics’s competitors?

    IFM Therapeutics, Inovio Pharmaceuticals, Gamida Cell, Kite Pharma, and Auron Therapeutics are some of the 27 competitors of Alyssum Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process